Journal
ASAIO JOURNAL
Volume 66, Issue 7, Pages 734-738Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MAT.0000000000001198
Keywords
COVID-19; pandemic; ARDS; extracorporeal membrane oxygenation
Categories
Ask authors/readers for more resources
SARS-CoV-2 may cause severe respiratory failure due to massive alveolar damage. Currently, no adequate curative therapy for Coronavirus Disease 2019 (COVID-19) disease exists. By considering overall impact of COVID-19 pandemic outbreak, an increased need of extracorporeal membrane oxygenation (ECMO) support becomes evident. We report on our preliminary institutional experience with COVID-19 patients receiving venovenous ECMO support.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
